Next Article in Journal
Biodegradable Nanoparticle for Cornea Drug Delivery: Focus Review
Next Article in Special Issue
Quantitative Cryo-TEM Reveals New Structural Details of Doxil-Like PEGylated Liposomal Doxorubicin Formulation
Previous Article in Journal
Ent-Peniciherqueinone Suppresses Acetaldehyde-Induced Cytotoxicity and Oxidative Stress by Inducing ALDH and Suppressing MAPK Signaling
Previous Article in Special Issue
Carbon Nano-Onions Reinforced Multilayered Thin Film System for Stimuli-Responsive Drug Release
Review

Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders

1
Institute of Pharmaceutical Research, GLA University, Mathura 281406, India
2
Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
3
Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, Finland
4
Faculty of Pharmacy, Uttar Pradesh University of Medical Sciences, Saifai, Etawah 206130, India
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(12), 1230; https://doi.org/10.3390/pharmaceutics12121230
Received: 24 November 2020 / Revised: 14 December 2020 / Accepted: 15 December 2020 / Published: 18 December 2020
(This article belongs to the Special Issue Development of Micro and Nano Systems for the Drug Delivery)
The treatment of various central nervous system (CNS) diseases has been challenging, despite the rapid development of several novel treatment approaches. The blood–brain barrier (BBB) is one of the major issues in the treatment of CNS diseases, having major role in the protection of the brain but simultaneously constituting the main limiting hurdle for drugs targeting the brain. Nasal drug delivery has gained significant interest for brain targeting over the past decades, wherein the drug is directly delivered to the brain by the trigeminal and olfactory pathway. Various novel and promising formulation approaches have been explored for drug targeting to the brain by nasal administration. Nanoemulsions have the potential to avoid problems, including low solubility, poor bioavailability, slow onset of action, and enzymatic degradation. The present review highlights research scenarios of nanoemulsions for nose-to-brain delivery for the management of CNS ailments classified on the basis of brain disorders and further identifies the areas that remain unexplored. The significance of the total dose delivered to the target region, biodistribution studies, and long-term toxicity studies have been identified as the key areas of future research. View Full-Text
Keywords: nanoemulsions; nose-to-brain delivery; CNS disorders; blood-brain barrier; olfactory pathway nanoemulsions; nose-to-brain delivery; CNS disorders; blood-brain barrier; olfactory pathway
Show Figures

Figure 1

MDPI and ACS Style

Bahadur, S.; Pardhi, D.M.; Rautio, J.; Rosenholm, J.M.; Pathak, K. Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders. Pharmaceutics 2020, 12, 1230. https://doi.org/10.3390/pharmaceutics12121230

AMA Style

Bahadur S, Pardhi DM, Rautio J, Rosenholm JM, Pathak K. Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders. Pharmaceutics. 2020; 12(12):1230. https://doi.org/10.3390/pharmaceutics12121230

Chicago/Turabian Style

Bahadur, Shiv, Dinesh M. Pardhi, Jarkko Rautio, Jessica M. Rosenholm, and Kamla Pathak. 2020. "Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders" Pharmaceutics 12, no. 12: 1230. https://doi.org/10.3390/pharmaceutics12121230

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop